Pasar al contenido principal

IMPLICACION DE LA GLIA EN TAUPATIA: NUEVAS DIANAS TERAPEUTICAS

PID2021-125986OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

  • Cuadrado, Antonio
  • Cazalla, Eduardo
  • Bach, A.
  • Bathish, B.
  • Naidu, S. D.
  • DeNicola, G. M.
  • Dinkova-Kostova, A. T.
  • Fernández-Ginés, Raquel
  • Grochot-Przeczek, A.
  • Hayes, J. D.
  • Kensler, T. W.
  • León, Rafael
  • Liby, K. T.
  • López, M. G.
  • Manda, Gina
  • Shivakumar, A. K.
  • Hakomäki, H.
  • Moerland, J. A.
  • Rojo, Ana I.
  • Sykiotis, G. P.
  • Taguchi, K.
  • Valverde, Ángela M.
  • Yamamoto, M.
  • Levonen, A. L.
This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone triterpenoids as multifunctional agents for prevention and treatment of chronic disease. Karen’s untimely passing is a huge loss for the Nrf2 community worldwide. Her kind personality and scientific rigour will be greatly missed., Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo., U.S. National Institutes of Health, R35 CA197222 (T.W.K.). PID- 2021-122766OB-1363 100 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU (A.M.V.). National Science Centre grant OPUS (2021/43/B/NZ4/02130) (A.G-P). Swiss National Science Foundation grants 310 030_212 558 and IZCOZ0_205 415 (G.P.S.). Lundbeck Foundation (grant R366-2021-270 (A.B.). Medical Research Council UK [MR/T014644/1 (J.D.H., B.B., A.T.D-K) and MR/ W023806/1 (A T.D-K)], Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1) (A.T.D-K), Tenovus Scotland (T22-08) (S.DN, A.T.D-K), and Reata Pharmaceuticals/Biogen (S.DN, A.T.D-K). Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121 421-I00, PDC2022-133 765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) (A.C., A.I.R.). FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505) (E.C.). Spanish Ministry of Science (grant PID2021-123481OB-I00), Comunidad de Madrid (grant P2022/BMD-7230-CAM-22), and Fundación Teófilo Hernando” (R.L.). Romania Ministry of Research, Innovation and Digitization through the Nucleu grant PN23.16.02.01 (G.M.). Spanish Ministry of science innovation and universities Refs PDC2022-133 809-I00 and PID2021-125986OB-I00 and General Council for Research and Innovation of the Community of Madrid Ref. P2022/BMD-7230 to (M.G.L.). NIH National Cancer Institute: NIH F31 CA275239 (J.A.M). Cancer Foundation Finland, Sigrid Juselius Foundation (A.L.L.).